Emergent BioSolutions Announces Key Financial Call for 2024

Author: Dylan Bailey Updated: 02-18-2025 09:00 AM

Emergent BioSolutions Prepares for Financial Year Review

Emergent BioSolutions Inc. (NYSE: EBS) is gearing up to unveil its financial results for the fourth quarter and full year 2024. This important event will be held on March 3, 2025, at 5:00 pm eastern time. The conference call will allow stakeholders to gain insights into the company’s performance and outlook.

How to Participate in the Call

To ensure that interested parties can join, Emergent BioSolutions has arranged a live conference call. Participants can easily access the call by visiting the Investor page on Emergent's official website and registering in advance. Telephone participants will receive a confirmation email which includes all necessary details to access the call.

Replay Access and Investor Events

For those who cannot attend the live call, a replay will be made available shortly after the event concludes. This replay can also be accessed through the Investor section on Emergent’s website, providing a convenient way for investors to stay updated on the company's performance.

Upcoming Presentation at J.P. Morgan’s Conference

In addition to the financial call, Emergent will take part in J.P. Morgan’s 2025 Leveraged Finance Conference. This event is slated for February 24, 2025, at 11:00 am eastern time. Participants can expect a brief presentation illuminating the company's strategy and initiatives.

Overview of Emergent BioSolutions

Emergent BioSolutions has been a pillar in the public health landscape for over 25 years. Their mission is clear: to protect and enhance life. Through a diverse portfolio of vaccines and therapeutics, the company is committed to addressing urgent public health threats. They not only develop innovative solutions but also provide contract development and manufacturing services tailored for pharmaceutical and biotechnology clients.

Aiming to Impact a Billion Lives

Emergent has set an ambitious goal to protect or enhance the lives of one billion people by 2030. This commitment underscores their dedication to innovation and public health, ensuring that they are well-prepared for future challenges.

Contact Information and Further Studies

For those wishing to learn more about Emergent BioSolutions or have any inquiries regarding investor relations, Richard S. Lindahl, the Executive Vice President and CFO, is the designated contact. His email address is provided for direct communication.

Media Inquiries

Furthermore, for media-related queries, Assal Hellmer, the Vice President of Communications at Emergent, is available. Both contacts can facilitate further engagement for stakeholders and media alike.

Frequently Asked Questions

When will Emergent BioSolutions hold its financial call?

The financial call is scheduled for March 3, 2025, at 5:00 pm eastern time.

How can I participate in the conference call?

Participation is via registration on Emergent’s Investor page, and participants will receive email confirmation with instructions.

Will there be a replay of the financial call?

Yes, a replay of the call will be available on the Investor section of Emergent’s website shortly after the live event.

What other events is Emergent participating in?

Emergent will also present at J.P. Morgan’s 2025 Leveraged Finance Conference on February 24, 2025, at 11:00 am eastern time.

How does Emergent BioSolutions aim to impact public health?

Emergent is focused on developing vaccines and therapeutics to address urgent public health challenges and has set a goal to protect or enhance one billion lives by 2030.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.